Linked Life Data

15986127

Source:http://linkedlifedata.com/resource/pubmed/id/15986127

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2005-6-29
pubmed:abstractText
There is a need for new endocrine agents that lack cross-resistance with currently available treatments to extend the endocrine treatment window and delay the need for cytotoxic chemotherapy. This retrospective analysis evaluated the response of postmenopausal patients with previously untreated metastatic/locally advanced breast cancer to further endocrine treatment following progression on first-line fulvestrant or tamoxifen. Patients received fulvestrant 250 mg (intramuscular injection every 28 days) plus matching tamoxifen placebo (once daily), or tamoxifen 20 mg (orally once daily) plus matching fulvestrant placebo (every 28 days) in a double-blind, randomized, phase III trial. Treatment continued until disease progression or withdrawal, when further endocrine therapy was initiated (at the treating physician's discretion). Information regarding subsequent therapies and responses was obtained by follow-up questionnaire. Two-hundred-and-forty-five questionnaires were returned (from 587 patients), 149 of which yielded follow-up data on patients receiving second-line endocrine therapy following fulvestrant (n=83) and tamoxifen (n=66). Second-line therapy produced objective responses (OR) in 6/44 (13.6%) and clinical benefit (CB) in 25/44 (56.8%) patients who had CB with fulvestrant and produced OR in 5/41 (12.2%) patients and CB in 27/41 (65.8%) patients who had CB with first-line tamoxifen. For patients deriving no CB from trial therapy, second-line therapy produced OR in 3/39 (7.7%) and CB in 15/39 (38.5%) patients in the fulvestrant group and OR in 4/25 (16.0%) and CB in 12/25 (48.0%) patients in the tamoxifen group. Results from this questionnaire-based study suggest that postmenopausal women with advanced breast cancer who respond to first-line fulvestrant or tamoxifen retain sensitivity to subsequent endocrine therapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0167-6806
pubmed:author
pubmed:issnType
Print
pubmed:volume
92
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
169-74
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:15986127-Adult, pubmed-meshheading:15986127-Aged, pubmed-meshheading:15986127-Antineoplastic Agents, Hormonal, pubmed-meshheading:15986127-Aromatase Inhibitors, pubmed-meshheading:15986127-Breast Neoplasms, pubmed-meshheading:15986127-Drug Resistance, Neoplasm, pubmed-meshheading:15986127-Estradiol, pubmed-meshheading:15986127-Female, pubmed-meshheading:15986127-Humans, pubmed-meshheading:15986127-Medroxyprogesterone Acetate, pubmed-meshheading:15986127-Megestrol Acetate, pubmed-meshheading:15986127-Middle Aged, pubmed-meshheading:15986127-Neoplasm Metastasis, pubmed-meshheading:15986127-Postmenopause, pubmed-meshheading:15986127-Retrospective Studies, pubmed-meshheading:15986127-Salvage Therapy, pubmed-meshheading:15986127-Tamoxifen, pubmed-meshheading:15986127-Treatment Outcome
pubmed:year
2005
pubmed:articleTitle
Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant.
pubmed:affiliation
Unit of Surgery, City Hospital, NG5 1PB, Nottingham, UK. John.Robertson@nottingham.ac.uk
pubmed:publicationType
Journal Article, Comparative Study